Compare BW & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BW | AMRN |
|---|---|---|
| Founded | 1867 | 1989 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.1M | 339.8M |
| IPO Year | N/A | 1993 |
| Metric | BW | AMRN |
|---|---|---|
| Price | $5.98 | $14.36 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 2 | 1 |
| Target Price | $5.50 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 3.4M | 80.9K |
| Earning Date | 11-04-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $721,285,000.00 | $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.85 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 80.30 | N/A |
| 52 Week Low | $0.22 | $7.08 |
| 52 Week High | $7.77 | $20.90 |
| Indicator | BW | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 52.21 | 35.29 |
| Support Level | $5.83 | $13.64 |
| Resistance Level | $6.51 | $14.67 |
| Average True Range (ATR) | 0.58 | 0.74 |
| MACD | -0.12 | -0.15 |
| Stochastic Oscillator | 38.24 | 24.21 |
Babcock & Wilcox Enterprises Inc is a power generation equipment supplier and servicing company that operates in three segments: B&W Renewable, B&W Environmental, and B&W Thermal. B&W Thermal, focuses on steam generation products and solutions for plants in the power generation, oil, and gas, and industrial sectors, generates the majority of the company's revenue. B&W Renewable focuses on sustainable power and heat generation while B&W Environmental focuses on emissions control. The company's customer base spans the industrial, electrical utility, and municipal industries located predominantly in the United States, Canada, Denmark, the United Kingdom, and other regions. Business in the U.S. contributes the vast majority of its revenue.
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.